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increased enormously, with many ﬁlling specialised niches
reﬂecting new disciplines and technologies. The emergence of
open-access journals has revolutionised the publication process,
maximising the availability of research data. Nevertheless, a wealth
of evidence shows that across many areas, the reporting of
biomedical research is often inadequate, leading to the view that
even if the science is sound, in many cases the publications
themselves are not “ﬁt for purpose,” meaning that incomplete
reporting of relevant information effectively renders many publi-
cations of limited value as instruments to inform policy or clinical
and scientiﬁc practice1e21. A recent review of clinical research
showed that there is considerable cumulative waste of ﬁnancial
resources at all stages of the research process, including as a result
of publications that are unusable due to poor reporting22. It is
unlikely that this issue is conﬁned to clinical research2e14,16e20.
Failure to describe research methods and to report results
appropriately therefore has potential scientiﬁc, ethical, and
economic implications for the entire research process and the
reputation of those involved in it. This is particularly true for animal
research, one of the most controversial areas of science. The largest
and most comprehensive review of published animal research
undertaken to date, to our knowledge, has highlighted serious
omissions in the way research using animals is reported5. The
survey, commissioned by the National Centre for the Replacement,
Reﬁnement and Reduction of Animals in Research (NC3Rs), a UK
Government-sponsored scientiﬁc organisation, found that only 59%
of the 271 randomly chosen articles assessed stated the hypothesis
or objective of the study, and the number and characteristics of the
animals used (i.e., species/strain, sex, and age/weight). Most of the
papers surveyed did not report using randomisation (87%) orq This article was previously published by PLoS Biology: Kilkenny C, Browne WJ,
Cuthill IC, Emerson M, Altman DG (2000) Improving Bioscience Research Reporting:
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doi:10.1371/journal.pbio.1000412, Published: June 29, 2010.
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unrestricted use, distribution, and reproduction in any medium, provided the original a
doi:10.1016/j.joca.2012.02.010blinding (86%) to reduce bias in animal selection and outcome
assessment. Only 70% of the publications that used statistical
methods fully described them and presented the results with
a measure of precision or variability5. These ﬁndings are a cause for
concern and are consistent with reviews of many research areas,
including clinical studies, published in recent years2e22.Good reporting is essential for peer review and to inform
future research
Scrutiny by scientiﬁc peers has long been the mainstay of
“quality control” for the publication process. The way that experi-
ments are reported, in terms of the level of detail of methods and
the presentation of key results, is crucial to the peer review process
and, indeed, the subsequent utility and validity of the knowledge
base that is used to inform future research. The onus is therefore on
the research community to ensure that their research articles
include all relevant information to allow in-depth critique, and to
avoiding duplicating studies and performing redundant experi-
ments. Ideally scientiﬁc publications should present sufﬁcient
information to allow a knowledgeable reader to understand what
was done, why, and how, and to assess the biological relevance of
the study and the reliability and validity of the ﬁndings. There
should also be enough information to allow the experiment to be
repeated23. The problem therefore is how to ensure that all relevant
information is included in research publications.Using reporting guidelines measurably improves the quality
of reporting
Evidence provided by reviews of published research suggests
that many researchers and peer reviewers would beneﬁt from
guidance about what information should be provided in a research
article. The CONSORT Statement for randomised controlled clinical
trials was one of the ﬁrst guidelines developed in response to this
need24,25. Since publication, an increasing number of leading
journals have supported CONSORT as part of their instructions to
authors26,27. As a result, convincing evidence is emerging that
CONSORT improves the quality and transparency of reports of
clinical trials28,29.ibuted under the terms of the Creative Commons Attribution License, which permits
uthor and source are credited.
Table II
Animal research: reporting in vivo experiments: the ARRIVE guidelines
Item Recommendation
Title 1 Provide as accurate and concise a description of the
Abstract 2 Provide an accurate summary of the background, res
principal ﬁndings, and conclusions of the study.
Introduction
Background 3 a. Include sufﬁcient scientiﬁc background (including
study, and explain the experimental approach and
b. Explain how and why the animal species and mo
relevance to human biology.
Objectives 4 Clearly describe the primary and any secondary obj
Methods
Ethical statement 5 Indicate the nature of the ethical review permission
institutional guidelines for the care and use of anim
Study design 6 For each experiment, give brief details of the study
a. The number of experimental and control groups.
b. Any steps taken to minimise the effects of subjecti
assessing results (e.g., if done, describe who was bli
c. The experimental unit (e.g., a single animal, group
complex study designs were carried out.
Experimental procedures 7 For each experiment and each experimental group,
a. How (e.g., drug formulation and dose, site and ro
procedure, method of euthanasia). Provide details o
b. When (e.g., time of day).
c. Where (e.g., home cage, laboratory, water maze).
d. Why (e.g., rationale for choice of speciﬁc anaesth
Experimental animals 8 a. Provide details of the animals used, including spe
weight (e.g., mean or median weight plus weight ra
b. Provide further relevant information such as the
knock-out or transgenic), genotype, health/immune
Housing and husbandry 9 Provide details of:
a. Housing (e.g., type of facility, e.g., speciﬁc pathog
tank shape and material etc. for ﬁsh).
b. Husbandry conditions (e.g., breeding programme
and water, environmental enrichment).
c. Welfare-related assessments and interventions th
Sample size 10 a. Specify the total number of animals used in each
b. Explain how the number of animals was decided
c. Indicate the number of independent replications
Allocating animals to
experimental groups
11 a. Give full details of how animals were allocated to
b. Describe the order in which the animals in the d
Experimental outcomes 12 Clearly deﬁne the primary and secondary experime
Statistical methods 13 a. Provide details of the statistical methods used for
b. Specify the unit of analysis for each dataset (e.g.,
c. Describe any methods used to assess whether the
Results
Baseline data 14 For each experimental group, report relevant charac
test-naïve) before treatment or testing (this inform
Numbers analysed 15 a. Report the number of animals in each group inclu
b. If any animals or data were not included in the a
Outcomes and estimation 16 Report the results for each analysis carried out, wit
Adverse events 17 a. Give details of all important adverse events in ea
b. Describe any modiﬁcations to the experimental p
Discussion
Interpretation/scientiﬁc
implications
18 a. Interpret the results, taking into account the study
b. Comment on the study limitations including any
associated with the results*.
c. Describe any implications of your experimental m
animals in research.
Generalisability/translation 19 Comment on whether, and how, the ﬁndings of thi
human biology.
Funding 20 List all funding sources (including grant number) an
doi:10.1371/journal.pbio.1000412.t002.
* Schulz, et al. (2010)24.
Table I
Funding bodies consulted
Name of Bioscience Research Funding Body
Medical Research Council
Biotechnology and Biological Sciences Research Council
Wellcome Trust
The Royal Society
Association of Medical Research Charities
British Heart Foundation
Parkinson’s Disease Society
doi:10.1371/journal.pbio.1000412.t001.
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opeddthere are currently more than 90 available for reporting
different types of health research, most of which have been pub-
lished in the last ten years (see http://www. equator-network.org
and references30,31). Guidelines have also been developed to
improve the reporting of other speciﬁc bioscience research areas
including metabolomics and gene expression studies32e37. Several
organisations support the case for improved reporting and
recommend the use of reporting guidelines, including the Inter-
national Committee of Medical Journal Editors, the Council ofcontent of the article as possible.
earch objectives (including details of the species or strain of animal used), key methods,
relevant references to previous work) to understand the motivation and context for the
rationale.
del being used can address the scientiﬁc objectives and, where appropriate, the study’s
ectives of the study, or speciﬁc hypotheses being tested.
s, relevant licences (e.g., Animal [Scientiﬁc Procedures] Act 1986), and national or
als, that cover the research.
design, including:
ve bias when allocating animals to treatment (e.g., randomisation procedure) and when
nded and when).
, or cage of animals). A time-line diagram or ﬂow chart can be useful to illustrate how
including controls, provide precise details of all procedures carried out. For example:
ute of administration, anaesthesia and analgesia used [including monitoring], surgical
f any specialist equipment used, including supplier(s).
etic, route of administration, drug dose used).
cies, strain, sex, developmental stage (e.g., mean or median age plus age range), and
nge).
source of animals, international strain nomenclature, genetic modiﬁcation status (e.g.,
status, drug- or testnaïve, previous procedures, etc.
en free (SPF); type of cage or housing; bedding material; number of cage companions;
, light/dark cycle, temperature, quality of water etc. for ﬁsh, type of food, access to food
at were carried out before, during, or after the experiment.
experiment and the number of animals in each experimental group.
. Provide details of any sample size calculation used.
of each experiment, if relevant.
experimental groups, including randomisation or matching if done.
ifferent experimental groups were treated and assessed.
ntal outcomes assessed (e.g., cell death, molecular markers, behavioural changes).
each analysis.
single animal, group of animals, single neuron).
data met the assumptions of the statistical approach.
teristics and health status of animals (e.g., weight, microbiological status, and drug- or
ation can often be tabulated).
ded in each analysis. Report absolute numbers (e.g., 10/20, not 50%*).
nalysis, explain why.
h a measure of precision (e.g., standard error or conﬁdence interval).
ch experimental group.
rotocols made to reduce adverse events.
objectives and hypotheses, current theory, and other relevant studies in the literature.
potential sources of bias, any limitations of the animal model, and the imprecision
ethods or ﬁndings for the replacement, reﬁnement, or reduction (the 3Rs) of the use of
s study are likely to translate to other species or systems, including any relevance to
d the role of the funder(s) in the study.
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Nufﬁeld Council for Bioethics38e41.
Improving the reporting of animal experimentsdthe ARRIVE
(animals in research: reporting in vivo experiments)
guidelines
Most bioscience journals currently provide little or no guidance on
what information to report when describing animal research42e50.
Our review found that 4% of the 271 journal articles assessed did not
report the number of animals used anywhere in the methods or the
results sections5. Reporting animal numbers is essential so that the
biological and statistical signiﬁcance of the experimental results can
be assessed or the data reanalysed, and is also necessary if the
experimental methods are to be repeated. Improved reporting of
these and other detailswill maximise the availability and utility of the
information gained from every animal and every experiment, pre-
venting unnecessary animal use in the future. To address this, we led
an initiative to produce guidelines for reporting animal research. The
guidelines, referred to as ARRIVE, have been developed using the
CONSORT Statement as their foundation24,25.
TheARRIVEguidelines consist of a checklist of 20 itemsdescribing
the minimum information that all scientiﬁc publications reporting
research using animals should include, such as the number and
speciﬁc characteristics of animals used (including species, strain, sex,
and genetic background); details of housing and husbandry; and the
experimental, statistical, andanalyticalmethods (includingdetails of
methodsused to reducebias suchas randomisation andblinding). All
the items in the checklist have been included to promote high-
quality, comprehensive reporting to allow an accurate critical
review of what was done and what was found.
Consensus and consultation are the corner-stones of the guideline
development process51. To maximise their utility, the ARRIVE guide-
lines have been prepared in consultationwith scientists, statisticians,
journal editors, and research funders.Weconvenedanexpertworking
group, comprising researchers and statisticians from a range of
disciplines, and journal editors from Nature Cell Biology, Science,
Laboratory Animals, and the British Journal of Pharmacology (see
Acknowledgments). At a one-day meeting in June 2009, the working
group agreed the scope and broad content of a draft set of guidelines
that were then used as the basis for a wider consultation with the
scientiﬁc community, involving researchers, and grant holders and
representatives of the major bioscience funding bodies including the
Medical Research Council, Wellcome Trust, Biotechnology and Bio-
logical Sciences Research Council, and The Royal Society (see Table I).
Feedback on the content and wording of the items was incorporated
into the ﬁnal version of the checklist. Further feedback on the content
utility of the guidelines is encouraged and sought.
The ARRIVE guidelines (see Table II) can be applied to any area of
bioscience research using laboratory animals, and the inherent
principles apply not only to reporting comparative experiments but
also to other study designs. Laboratory animal refers to any species
of animal undergoing an experimental procedure in a research
laboratory or formal test setting. The guidelines are not intended to
be mandatory or absolutely prescriptive, nor to standardise or
formalise the structure of reporting. Rather they provide a checklist
that can be used to guide authors preparing manuscripts for
publication, and by those involved in peer review for quality
assurance, to ensure completeness and transparency.
Improved reporting will maximise the output of published
research
These guidelines were developed to maximise the output from
research using animals by optimising the information that isprovided in publications on the design, conduct, and analysis of the
experiments. The need for such guidelines is further illustrated by
the systematic reviews of animal research that have been carried
out to assess the efﬁcacy of various drugs and interventions in
animal models8,9,13,52e55. Well-designed and -reported animal
studies are the essential building blocks from which such
a systematic review is constructed. The reviews have found that, in
many cases, reporting omissions, in addition to the limitations of
the animal models used in the individual studies assessed in the
review, are a barrier to reaching any useful conclusion about the
efﬁcacy of the drugs and interventions being compared2,3.
Driving improvements in reporting research using animals will
require the collective efforts of authors, journal editors, peer
reviewers, and funding bodies. There is no single simple or rapid
solution, but the ARRIVE guidelines provide a practical resource to
aid these improvements. The guidelineswill be published in several
leading bioscience research journals simultaneously56e60, and
publishers have already endorsed the guidelines by including them
in their journal Instructions to Authors subsequent to publication.
The NC3Rs will continue to work with journal editors to extend the
range of journals adopting the guidelines, and with the scientiﬁc
community to disseminate the guidelines as widely as possible
(http://www.nc3rs.org.uk/ARRIVE).
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